Unique ID issued by UMIN | UMIN000016553 |
---|---|
Receipt number | R000019185 |
Scientific Title | Phase 2 study of bevacizumab beyond progression disease for glioblastoma treated with key therapeutics. |
Date of disclosure of the study information | 2015/02/28 |
Last modified on | 2023/01/17 08:37:23 |
Phase 2 study of bevacizumab beyond progression disease for glioblastoma treated with key therapeutics.
BIOMARK
Phase 2 study of bevacizumab beyond progression disease for glioblastoma treated with key therapeutics.
BIOMARK
Japan |
Newly diagnosed glioblastoma
Neurosurgery |
Malignancy
NO
The aim of this study is to evaluate efficacy and safety of temozolomide plus bevacizumab with radiotherapy as the 1st line treatment, and of subsequent treatment of bevacizmumab as the 2nd line treatment in newly diagnosed glioblastoma.
Safety,Efficacy
Exploratory
Pragmatic
Phase II
2-years survival rate of patients who can be treated with continuous bevacizumab from the 1st line treatment to the 2nd line treatment.
1). 2-years survival rate of all patients.
2). Overall survival of patients who can treated with continuous bevacizumab from the 1st line treatment to the 2nd line treatment.
3). Overall survival of all patients.
4). Progression free survival(the 1st line treatment).
5). KPS maintenance term(the 1st line treatment).
6). Response rate(the 1st line treatment).
7). QoL (Quality of Life):EORTC QLQ-C30,EORTC BN20,MDASI-BT
8). NCF (Neurocognitive Function):MMSE,HVLT-R,TMT,COWA
9). Safety
Interventional
Single arm
Non-randomized
Open -no one is blinded
Historical
1
Treatment
Medicine |
Temozolomide plus bevacizumab with radiotherapy.
Subsequent treatment of continuous bevacizumab as 2nd line treatment
20 | years-old | <= |
75 | years-old | >= |
Male and Female
(1)Supratentorial, newly diagnosed and histologically confirmed glioblastoma (GBM, WHO GradeIV).
(2)Registration should be completed >=7days and <21days after craniotomy or biopsy, without drainage and infection. Surgical specimens should be available for genetic analyses.
(3)Patients without dissemination nor gliomatosis cerebri.
(4)Have provided written informed consent to enroll and supply the specimens prior to any trial specific procedures.
(5)Age >=20 years, <=75 years.
(6)Karnofsky performance status >=60.
(7)Regardless of the presence of mesurable lesions.
(8)Estimated life expectancy at least 3 months.
(9)Adequate organ function indicated by all of the following.
When there are more than one test results, the latest should be adopted.
1).neutrophil count >=1,500/mm3
2).Platelet count >=10.0*the fourth power of10/mm3
3).Haemoglobin >=9.0g/dL
4).Total bilirubin <=1.5mg/dL
5).AST, ALT <=120IU/L
6).Serum creatinine <=1.5mg/dL
7).Proteinuria <=1+
8).PT-INR <=1.5
NOTE:When treated with warfarin; 1.5<=, <=2.5
(1)Evidence of recent haemorrhage on postoperative magnetic resonance imaging of the brain.
(2)Any prior chemotherapy, radiotherapy or immunotherapy (including vaccine therapy) for GBM.
(3)Inadequately controlled hypertension.
(4)Prior history of hypertensive crisis, or hypertensive encephalopathy.
(5)New York Heart Association Grade II or greater congestive heart failure.
(6)Other malignancy within 5 years prior to trial enrolment.
(7)Active infection requiring systemic treatment.
(8)Diabetic with continued insulin treatment or uncontrolled.
(9)Have received continued administration of steroids to some systemic disease.
(10)Any of the following medical history within 6 months prior to registration.
1)myocardial infarction or unstable angina
2)stroke or TIAs
3)Significant vascular disease
4)Abdominal fistula or perforation of the digestive tract
5)Intracranial abscess
(11)History of >= grade 2 hemoptysis within 28 days prior to registration.
(12)Evidence of bleeding diathesis or coagulopathy.
(13)Serious non-healing wound, active ulcer or untreated bone fracture.
(14)Pregnancy or lactation, as well as fertile women and men unwilling or unable to use effective means of contraception.
(15)Known hypersensitivity to any of the trial drugs.
(16)Patients with allergy to gadolinium.
(17)Patients with active hepatic disease.
(18)Attending physician has determined unsuitable to participate in the study.
90
1st name | Ryo |
Middle name | |
Last name | Nishikawa |
Saitama International Medical Center, Saitama Medical University
Department of Neuro-Oncology/Neurosurgery
350-1298
1397-1 Yamane, Hidaka-shi, Saitama, 350-1298
042-984-4111
rnishika@saitama-med.ac.jp
1st name | Ryo |
Middle name | |
Last name | Nishikawa |
Saitama International Medical Center, Saitama Medical University
Department of Neuro-Oncology/Neurosurgery
350-1298
1397-1 Yamane, Hidaka-shi, Saitama, 350-1298
042-984-4111
rnishika@saitama-med.ac.jp
EPS Corporation
CHUGAI PHARMACUTICAL CO.,LTD.
Profit organization
Japan
MINS IRB
5-20-9-401, Mita, Minato-ku, Tokyo
03-6416-1868
npo-mins@j-irb.com
NO
北海道大学病院(北海道)、東北大学病院(宮城県)、山形大学医学部附属病院(山形県)、岩手医科大学附属病院(岩手県)、秋田大学医学部附属病院(秋田県)、順天堂大学医学部附属順天堂医院(東京都)、東京大学医学部附属病院(東京都)、国立がん研究センター中央病院(東京都)、日本赤十字社医療センター(東京都)、杏林大学医学部付属病院(東京都)、千葉県がんセンター(千葉県)、埼玉医科大学国際医療センター(埼玉県)、新潟大学医歯学総合病院(新潟県)、筑波大学附属病院(茨城県)、獨協医科大学病院(栃木県)、北里大学病院(神奈川県)、名古屋大学医学部附属病院(愛知県)、藤田医科大学病院(愛知県)、京都大学医学部附属病院(京都府)、国立病院機構京都医療センター(京都府)、国立病院機構大阪医療センター(大阪府)、大阪医科大学附属病院(大阪府)、奈良県立医科大学附属病院(奈良県)、和歌山県立医科大学附属病院(和歌山県)、神戸大学医学部附属病院(兵庫県)、広島大学病院(広島県)、岡山大学病院(岡山県)、愛媛大学附属病院(愛媛県)、九州大学病院(福岡県)、久留米大学病院(福岡県)、熊本大学医学部附属病院(熊本県)、宮崎大学医学部付属病院(宮崎県)、鹿児島大学病院(鹿児島県)、琉球大学医学部附属病院(沖縄県)、弘前大学医学部付属病院(青森県)、東京医科歯科大学医学部付属病院(東京都)、金沢大学附属病院(石川県)、佐賀大学医学部附属病院(佐賀県)、京都府立医科大学病院(京都府)
2015 | Year | 02 | Month | 28 | Day |
unpublished
Published
https://doi.org/10.3390/cancers14225522
94
The primary endpoint of BIOMARK was not met (the 2-year survival rate in the BBP group was 27.0% vs. the target of 50%). BBP was initiated in only a small subset (27/90 patients) of the entire cohort, where MGMT-unmethylated tumors were predominant. We identified a novel expression cluster that may predict the prognosis of GBM patients treated with bevacizumab. Further validation of the predictive value of the novel expression classifier is warranted.
2022 | Year | 12 | Month | 07 | Day |
2022 | Year | 11 | Month | 10 | Day |
The median age was 60.5 years (range, 22-75 years). Approximately half of patients (52%) had a KPS of 50-80. Most (79%) were not receiving corticosteroids at baseline. MGMT gene promoter methylation was observed in 33% of patients. The percentage of patients with WT IDH1 was 93%, whereas 5% had IDH1 mutations. Those diffuse gliomas with histological features of GBM, which were diagnosed as GBM according to the WHO Classification, 4th Ed., at the time of enrollment, have been re-classified as Astrocytoma, IDH-mutant, CNS WHO grade 4 in the latest WHO Classification, 5th Ed. (WHO CNS5). As such, survival analyses primarily focused on the IDH-wildtype tumors. TERT gene promoter mutation was observed in 66% of patients.
From June 2015 to December 2016, 94 patients were enrolled from 39 sites in Japan.
Data cutoff was 17 January 2019, when all outcome surveys were completed, corresponding with the protocol-specified follow-up. In total, 83 patients discontinued. The major reasons were: AEs (34.0%), progression/recurrence during the second-line treatment (24.5%), and patient decline (18.1%). All 94 patients received protocol-defined primary therapy (Safety Analysis Set). Of these, 90 were diagnosed with GBM by central pathological review and were included in the FAS. Twenty-seven patients received protocol-defined secondary therapy (BBP), and of these, 25 without protocol deviations were included in the BBP group.
Regarding safety, the protocol-defined therapies were generally well tolerated. Frequently observed AEs of special interest for bevacizumab (all grades) included hypertension (42.6%), proteinuria (29.8%), and mucocutaneous bleeding (10.6%). Other common AEs including myelosuppression (all grades) were lymphopenia (50%), neutropenia (27.7%), thrombocytopenia (19.1%), anemia (5.3%), appetite loss (30.9%), constipation (30.9%), nausea (18.1%), and fatigue (13.8%).
Common Grade 3 or 4 AEs were hypertension (29.8%), wound healing complications and cerebral hemorrhage (2.1%, each), and lymphopenia (41.5%). The occurrence of Grade >=3 arterial thromboembolic events was 1.1%. No new unknown toxicities were encountered.
In the FAS (n = 90), mOS was 25.0 months (95% CI: 21.7-26.3) and mPFS was 14.9 months (95% CI: 11.8-18.3). The 2-year survival rate was 52.4% (90% CI: 43.3%-60.8%), and the 2-year PFS rate was 25.7% (90% CI: 18.3%-33.7%). In patients in the FAS solely with IDH1-WT GBM (n = 85), the mOS was 24.8 months (95% CI: 19.7-26.3) and the mPFS was 14.8 months (95% CI: 11.7-17.2). In the BBP group (n = 25, all IDH1-WT), the mOS and mPFS from the initial diagnosis were 16.8 months (95% CI: 14.0-23.2) and 11.4 months (95% CI: 9.0-17.1), respectively. The 2-year survival rate was 27.0% (90% CI: 13.6%-42.4%), which did not meet the prespecified target value (50%) (primary endpoint). The 2-year PFS rate was 8.0% (90% CI: 2.0%-19.7%). In the BBP group, mOS and mPFS from the initiation of BBP were 5.8 months (95% CI: 3.9-6.9) and 1.9 months (95% CI: 1.1-2.9), respectively.
Completed
2015 | Year | 01 | Month | 30 | Day |
2015 | Year | 01 | Month | 30 | Day |
2015 | Year | 06 | Month | 02 | Day |
2019 | Year | 01 | Month | 17 | Day |
2019 | Year | 02 | Month | 25 | Day |
2019 | Year | 02 | Month | 28 | Day |
2019 | Year | 03 | Month | 31 | Day |
Genome information management:
This study is exempt from "Ethical Guidelines for Human Genome and Genetic Sequencing Research " as its research object is only somatic cell genome information of tumor tissue. However, the study is carried out with sufficient attention to the donor's personal information.
2015 | Year | 02 | Month | 16 | Day |
2023 | Year | 01 | Month | 17 | Day |
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000019185
Research Plan | |
---|---|
Registered date | File name |
Research case data specifications | |
---|---|
Registered date | File name |
Research case data | |
---|---|
Registered date | File name |